<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE322nnn/GSE322796/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE322796</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy</name><description>B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for immunity remain incompletely examined. Here, we define the mucosal pathophysiology of ciltacabtagene autoleucel CAR-T cell-induced enterocolitis (CAR-TEC), a severe complication of B cell maturation antigen (BCMA)-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry, and tissue imaging of intestinal biopsies from patients with CAR-TEC (n=10), CAR-T cell treated controls (CAR-TCTRL) without enterocolitis (n=7), and healthy volunteers (n=26), we identify profound depletion of mucosal B cells and plasma cells (PCs) accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal, and glial cell remodeling to be associated with CAR-TEC. Cell-cell communication analyses suggest a compensated mucosal state in CAR-TCTRL, while telocyte-driven stromal niche dysfunction was noted in CAR-TEC. Interferon and JAK-STAT-associated reprogramming was noted across stromal, endothelial, and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib, an oral selective JAK1 inhibitor resulted in clinical, endoscopic and histologic improvement in 2 individuals with CAR-TEC. Our findings define CAR-TEC as a multi-compartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.</description><dates><publication>2026/07/29</publication></dates><accession>GSE322796</accession><cross_references><GSM>GSM9742309</GSM><GSM>GSM9742311</GSM><GSM>GSM9742310</GSM><GSM>GSM9558960</GSM><GSM>GSM9558952</GSM><GSM>GSM9558942</GSM><GSM>GSM9558953</GSM><GSM>GSM9558961</GSM><GSM>GSM9558950</GSM><GSM>GSM9558962</GSM><GSM>GSM9558951</GSM><GSM>GSM9558956</GSM><GSM>GSM9558945</GSM><GSM>GSM9558957</GSM><GSM>GSM9558946</GSM><GSM>GSM9558954</GSM><GSM>GSM9558943</GSM><GSM>GSM9558955</GSM><GSM>GSM9558949</GSM><GSM>GSM9558958</GSM><GSM>GSM9558947</GSM><GSM>GSM9558959</GSM><GSM>GSM9558948</GSM><GPL>34281</GPL><GSE>322796</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>